Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol

Abstract

To determine the efficacy of the treat and extend (TAE) protocol with intravitreal bevacizumab (IVB) for managing diabetic macular edema (DME). Retrospective, single-center study. For this retrospective study, 42 eyes of 42 patients were initially treated with 3 consecutive monthly IVB injections (loading phase), after which they were selected for different additional therapies. For the TAE protocol, the baseline treatment interval was selected to be 8 weeks and was sequentially lengthened by 2 weeks if the central macular thickness (CMT) was <300μm at 2 consecutive examinations. Among the 42 eyes, 8 eyes (19.0%) received the TAE treatment for 2 years. The BCVA was improved significantly from 0.37±0.04 before treatment to 0.19±0.04 logMAR units at 2 years after the TAE determined IVB injections (P